Indications and diagnostic yield of small-bowel capsule endoscopy in a real-world setting.


Journal

BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547

Informations de publication

Date de publication:
08 Jun 2020
Historique:
received: 02 12 2019
accepted: 01 06 2020
entrez: 10 6 2020
pubmed: 10 6 2020
medline: 19 3 2021
Statut: epublish

Résumé

Indications and diagnostic yield of small-bowel video capsule endoscopy (SB-VCE) are communicated in recent clinical academic guidelines. However, guidelines are based mainly on relatively few, small, selection-biased studies at experienced centers, and thus we lack information on indications and diagnostic yield of SB-VCE in the real-world community setting. The aim of the study was to evaluate indications and diagnostic yield of SB-VCE in the real-world community setting. Our local VCE clinical database was used to identify patients undergoing SB-VCE procedures over a 7-year period (2011-2018). Patients were broadly referred and underwent SB-VCE using PillCam™ SB 2 and SB 3 capsule systems. Procedures were reviewed by local endoscopists, who had undergone similar formal SB-VCE review training. Medical reports of the procedures were composed as such. We retrospectively reviewed all reports and gathered data regarding indications and findings. Diagnostic yield was considered positive if SB-VCE visualized any type of clinically significant pathological finding. 536 SB-VCE procedures in 516 patients were included in final assessment. Patient mean (± SD) age was 50 ± 20 years with approximately even female/male ratio (275:241). The overall proportion of positive findings was 42% (225/536). The two main indications were obscure gastrointestinal bleeding (occult/anemia or overt/active, OGIB) of 46% (246/536) and definite/suspected Crohn's disease (CD) of 39% (210/536). Positive SB-VCE findings were obtained in 44% (108/246) of procedures with indication of OGIB and in 50% (104/210) of procedures with indication of CD. The indications for SB-VCE are largely consistent with guidelines but with an apparently relatively low diagnostic yield in our real-world community setting.

Sections du résumé

BACKGROUND BACKGROUND
Indications and diagnostic yield of small-bowel video capsule endoscopy (SB-VCE) are communicated in recent clinical academic guidelines. However, guidelines are based mainly on relatively few, small, selection-biased studies at experienced centers, and thus we lack information on indications and diagnostic yield of SB-VCE in the real-world community setting. The aim of the study was to evaluate indications and diagnostic yield of SB-VCE in the real-world community setting.
METHODS METHODS
Our local VCE clinical database was used to identify patients undergoing SB-VCE procedures over a 7-year period (2011-2018). Patients were broadly referred and underwent SB-VCE using PillCam™ SB 2 and SB 3 capsule systems. Procedures were reviewed by local endoscopists, who had undergone similar formal SB-VCE review training. Medical reports of the procedures were composed as such. We retrospectively reviewed all reports and gathered data regarding indications and findings. Diagnostic yield was considered positive if SB-VCE visualized any type of clinically significant pathological finding.
RESULTS RESULTS
536 SB-VCE procedures in 516 patients were included in final assessment. Patient mean (± SD) age was 50 ± 20 years with approximately even female/male ratio (275:241). The overall proportion of positive findings was 42% (225/536). The two main indications were obscure gastrointestinal bleeding (occult/anemia or overt/active, OGIB) of 46% (246/536) and definite/suspected Crohn's disease (CD) of 39% (210/536). Positive SB-VCE findings were obtained in 44% (108/246) of procedures with indication of OGIB and in 50% (104/210) of procedures with indication of CD.
CONCLUSIONS CONCLUSIONS
The indications for SB-VCE are largely consistent with guidelines but with an apparently relatively low diagnostic yield in our real-world community setting.

Identifiants

pubmed: 32513115
doi: 10.1186/s12876-020-01326-8
pii: 10.1186/s12876-020-01326-8
pmc: PMC7282185
doi:

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

177

Références

Can J Gastroenterol Hepatol. 2015 Mar;29(2):85-90
pubmed: 25803018
Gastrointest Endosc. 2013 May;77(5):761-6
pubmed: 23375526
Gastroenterology. 2010 May;138(5):1673-1680.e1; quiz e11-2
pubmed: 20138043
J Gastroenterol Hepatol. 2011 May;26(5):796-801
pubmed: 21155884
Endoscopy. 2015 Apr;47(4):352-76
pubmed: 25826168
Dig Liver Dis. 2012 Dec;44(12):1006-11
pubmed: 22858420
Rev Esp Enferm Dig. 2018 Mar;110(3):155-159
pubmed: 29278000
Gastrointest Endosc. 2010 Feb;71(2):280-6
pubmed: 20152309
Gastrointest Endosc. 2019 Jan;89(1):33-43.e4
pubmed: 29935143
Dig Dis Sci. 2018 Sep;63(9):2244-2250
pubmed: 29767393
Am J Gastroenterol. 2012 Sep;107(9):1370-6
pubmed: 22825363
Am J Gastroenterol. 2010 Jun;105(6):1240-8; quiz 1249
pubmed: 20029412
Dig Liver Dis. 2011 Feb;43(2):126-31
pubmed: 20817579
Endoscopy. 2012 Apr;44(4):337-42
pubmed: 22389234
Front Med (Lausanne). 2016 Feb 10;3:6
pubmed: 26904544
Gastroenterology. 2017 Feb;152(3):497-514
pubmed: 28063287

Auteurs

André Artan Kharazmi (AA)

Digestive Disease Center, Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, DK-2400, Copenhagen NV, Denmark. Andre_ak_1994@hotmail.com.

Saeid Aslani (S)

Digestive Disease Center, Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, DK-2400, Copenhagen NV, Denmark.

Malene Fey Kristiansen (MF)

Digestive Disease Center, Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, DK-2400, Copenhagen NV, Denmark.

Eva Efsen Dahl (EE)

Digestive Disease Center, Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, DK-2400, Copenhagen NV, Denmark.

Mark Berner-Hansen (M)

Digestive Disease Center, Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, DK-2400, Copenhagen NV, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH